secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-05-13T12:41:07+00:00
Accession:  0001178913-26-002624
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site
--------------------------------------------------------------------------------

- Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France center of excellence.
- Tel Aviv Sourasky Medical Center Helsinki Ethics Committee approved planned Phase 2/3 trial of SIL204 in LAPC.
- SIL204 is a next-generation siRNA therapy targeting mutated KRAS, most common oncogenic driver in cancers.
- Phase 2/3 trial to evaluate SIL204 with standard-of-care chemo using dual-route (intratumoral + systemic) administration.
- Israeli Ministry of Health already approved the trial; CTA submitted to Germany; preparing for first patient dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002624/0001178913-26-002624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002624/zk2635307.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer